Progress in Schizophrenia Research and Treatment
This section contains a compilation of recent publications that have shaped the thinking in the field as well as classic works that remain important to the subject reviewed in this issue. This bibliography has been compiled by experts in the field and members of the editorial and advisory boards. Entries are listed chronologically and within topics and years by first author. Articles from the bibliography that are reprinted in this issue are in bold type.
Comparative effectiveness of antipsychotics for risk of attempted or completed suicide among persons with schizophrenia. Schizophr Bull, in pressGoogle Scholar
:Cognitive remediation for schizophrenia: an expert working group white paper on core techniques. Schizophr Res 2020; 215:49–53Crossref, Google Scholar
:Inflammation and negative symptoms of schizophrenia: implications for reward processing and motivational deficits. Front Psychiatry 2020; 11:46Crossref, Google Scholar
:Safety of psychotropic medications in people with COVID-19: evidence review and practical recommendations. BMC Med 2020; 18:215Crossref, Google Scholar
:The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research. NPJ Schizophr 2020; 6:1Crossref, Google Scholar
:Correlates of future violence in people being treated for schizophrenia. Am J Psychiatry 2019; 176:694–701Crossref, Google Scholar
:The nuts and bolts of cognitive remediation: exploring how different training components relate to cognitive and functional gains. Schizophr Res 2019; 203:12–16Crossref, Google Scholar
:Resistance is not futile: treatment-refractory schizophrenia—overview, evaluation and treatment. Expert Opin Pharmacother 2019; 20:11–24Crossref, Google Scholar
:Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. (published correction appears in Lancet. 2019 Sep 14;394(10202:918) Lancet 2019; 394:939–951Crossref, Google Scholar
:Editorial: neurobiology, clinical course, and therapeutic approaches of treatment-resistant schizophrenia: toward an integrated view. Front Psychiatry 2019; 10:870Crossref, Google Scholar
:Self-management interventions for people with severe mental illness: systematic review and meta-analysis. Br J Psychiatry 2019; 214:260–268Crossref, Google Scholar
:Schizophrenia. N Engl J Med 2019; 381:1753–1761Crossref, Google Scholar
:Clozapine augmentation strategies. Ment Health Clin 2019; 9:336–348Crossref, Google Scholar
:Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis. Psychopharmacology (Berl) 2019; 236:545–559Crossref, Google Scholar
:Association of antipsychotic polypharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia. JAMA Psychiatry 2019; 76:499–507Crossref, Google Scholar
:Risk factors for suicidality in patients with schizophrenia: a systematic review, meta-analysis, and meta-regression of 96 studies. Schizophr Bull 2018; 44:787–797Crossref, Google Scholar
:Management of depression in patients with schizophrenia spectrum disorders: a critical review of international guidelines. Acta Psychiatr Scand 2018; 138:289–299Crossref, Google Scholar
:A randomized, double-blind, placebo-controlled clinical trial of tocilizuamb, an interleukin-6 receptor antibody, for residual symptoms in schizophrenia. Neuropsychopharmacology 2018; 43:1317–1323Crossref, Google Scholar
:Controversies in computerized cognitive training. Biol Psychiatry Cogn Neurosci Neuroimaging 2018; 3:907–915Crossref, Google Scholar
:Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: a review of systematic reviews. BMC Psychiatry 2018; 18:275Crossref, Google Scholar
:Dopamine, psychosis and schizophrenia: the widening gap between basic and clinical neuroscience. Transl Psychiatry 2018; 8:30Crossref, Google Scholar
:The relationship between negative symptoms and depression in schizophrenia: a systematic review. Acta Psychiatr Scand 2018; 137:380–390Crossref, Google Scholar
:The assessment and treatment of antipsychotic-induced akathisia. Can J Psychiatry 2018; 63:719–729Crossref, Google Scholar
:What causes psychosis? An umbrella review of risk and protective factors. World Psychiatry 2018; 17:49–66Crossref, Google Scholar
:Comparative effectiveness of antipsychotic drugs for rehospitalization in schizophrenia—a nationwide study with 20-year follow-up. Schizophr Bull 2018; 44:1381–1387Crossref, Google Scholar
:Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence. JAMA Psychiatry 2017; 74:675–684Crossref, Google Scholar
:Improving outcomes of first-episode psychosis: an overview. World Psychiatry 2017; 16:251–265Crossref, Google Scholar
:The long-term effects of antipsychotic medication on clinical course in schizophrenia. Am J Psychiatry 2017; 174:840–849Crossref, Google Scholar
:Current and potential pharmacological and psychosocial interventions for anxiety symptoms and disorders in patients with schizophrenia: structured review. Hum Psychopharmacol 2017; 32Crossref, Google Scholar
:Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. Am J Psychiatry 2017; 174:216–229Crossref, Google Scholar
:The current conceptualization of negative symptoms in schizophrenia. World Psychiatry 2017; 16:14–24Crossref, Google Scholar
:https://effectivehealthcare.ahrq.gov/topics/schizophrenia-adult/research-2017.Google Scholar
: Treatments for schizophrenia in adults: a systematic review. comparative effectiveness review no. 198. AHRQ pub no. 17(18)-EHC031-EF. Rockville, MD, Agency for Healthcare Research and Quality, Oct 2017.Remission of psychosis in treatment-resistant schizophrenia following bone marrow transplantation: a case report. Front Psychiatry 2017; 8:174Crossref, Google Scholar
:Mortality and self-harm in association with clozapine in treatment-resistant schizophrenia. Am J Psychiatry 2017; 174:990–998Crossref, Google Scholar
:Guide to the management of clozapine-related tolerability and safety concerns. Clin Schizophr Relat Psychoses 2016; 10:163–177Crossref, Google Scholar
:Treatment engagement of individuals experiencing mental illness: review and update. World Psychiatry 2016; 15:13–20Crossref, Google Scholar
:efficacy and safety of antidepressants added to antipsychotics for schizophrenia: a systematic review and meta-analysis. Am J Psychiatry 2016; 173:876–886Crossref, Google Scholar
:An open-label, pilot trial of adjunctive tocilizumab in schizophrenia. J Clin Psychiatry 2016; 77:275–276Crossref, Google Scholar
:Schizophrenia risk from complex variation of complement component 4. Nature 2016; 530:177–183Crossref, Google Scholar
:Comparative effectiveness of clozapine and standard antipsychotic treatment in adults with schizophrenia. Am J Psychiatry 2016; 173:166–173Crossref, Google Scholar
:Beyond psychopharmacology: emerging psychosocial interventions for core symptoms of schizophrenia. Focus 2016; 14:315–327Link, Google Scholar
:Treatment adherence in schizophrenia: a patient-level meta-analysis of combined CATIE and EUFEST studies. Eur Neuropsychopharmacol 2015; 25:1158–1166Crossref, Google Scholar
:Neuroinflammation and white matter pathology in schizophrenia: systematic review. Schizophr Res 2015; 161:102–112Crossref, Google Scholar
:Electroconvulsive therapy augmentation in clozapine-resistant schizophrenia: a prospective, randomized study. Am J Psychiatry 2015; 172:52–58Crossref, Google Scholar
:Severe chronic psychosis after allogeneic SCT from a schizophrenic sibling. Bone Marrow Transplant 2015; 50:153–154Crossref, Google Scholar
:Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register study. Am J Psychiatry 2011; 168:1303–1310Crossref, Google Scholar
:Workshop on defining the significance of progressive brain change in schizophrenia: December 12, 2008 American College of Neuropsychopharmacology (ACNP) All-Day Satellite, Scottsdale, Arizona. The Rapporteurs’ Report. Schizophr Res 2009; 112:32–45Crossref, Google Scholar
:Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am J Psychiatry 2010; 167:261–280Crossref, Google Scholar
:Cognitive-behavioral therapy for medication-resistant psychosis: a meta-analytic review. Psychiatr Serv 2014; 65:874–880Link, Google Scholar
:Identifying cognitive remediation change through computational modelling--effects on reinforcement learning in schizophrenia. Schizophr Bull 2014; 40:1422–1432Crossref, Google Scholar
:Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull 2009; 35:443–457Crossref, Google Scholar
:Safety and tolerability of antipsychotic polypharmacy. Expert Opin Drug Saf 2012; 11:527–542Crossref, Google Scholar
:Schizophrenia: an integrated sociodevelopmental–cognitive model. Lancet 2014; 383:1677–1687Crossref, Google Scholar
:Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update. Schizophr Bull 2014; 40:181–191Crossref, Google Scholar
:Psychological interventions for psychosis: a meta-analysis of comparative outcome studies. Am J Psychiatry 2014; 171:523–538Crossref, Google Scholar
:Hyperactivity and hyperconnectivity of the default network in schizophrenia and in first-degree relatives of persons with schizophrenia. Proc Natl Acad Sci USA 2009; 106:1279–1284Crossref, Google Scholar
: